Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1989-05-25
1990-05-15
Dixon, Jr., William R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514358, A61K 31135
Patent
active
049258605
ABSTRACT:
Described is a stable pharmaceutical composition of 3-(hydroxymethyl-5,5-diphenylhydantoin disodium phosphate ester, the prodrug of 5,5-diphenylhydantoin (phenytoin) a commonly used drug for the treatment and management of epilepsy and other types of convulsive states. It has been found that degradation of the prodrug to phenytoin can be controlled by controlling the pH of the composition. Controlling the pH to between 8.3 to 9.4 results in the production of diphenylglycinamide as the primary degradant and minimization of degradation to phenytoin. If the pH is maintained at a lower or higher value, then the degradation pattern changes, with earlier than expected product failure.
REFERENCES:
patent: 4260769 (1981-04-01), Stella
Varia et al., "Phenytoin Prodrug IV: Hydrolysis of Various 3-(Hydroxymethyl)Phenytoin Esters", Journal of Pharmaceutical Sciences, vol. 73, No. 8, Aug. 1984, (pp. 1068-1090).
Herbranson Dale E.
Rosenberg Leonard S.
Speicher Earl R.
Dixon Jr. William R.
E. I. Du Pont de Nemours and Company
Hunter, Jr. J. M.
LandOfFree
Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphe does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphe, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphe will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-621785